IFP Advisors’s Actuate Therapeutics ACTU Stock Holding History

IFP Advisors’s Portfolio ACTU Stock Details ACTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$20	Sell	26 -47	-64%	-$56	﹤0.01%	5144
2026 Q2	$112	Buy	73 +72	+7,200%	+$167	﹤0.01%	4947
2026 Q1	$3	Buy	+1	New	+$4	﹤0.01%	5006

Other funds holding ACTU

Gleason Group Prospect, Kentucky $1.13B AUM 12.68% 1-Year Est. Return

Sowell Financial Services North Little Rock, Arkansas $3.61B AUM 22.22% 1-Year Est. Return

GRWP

Green Ridge Wealth Planning Montville, New Jersey $249M AUM 26.89% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.34% 1-Year Est. Return

IFP Advisors's ACTU Position: Q3 2026 in Review

IFP Advisors reduced its Actuate Therapeutics (ACTU) stake by 64% in Q3 2026, selling an estimated $56 and leaving 26 shares worth $20. The position accounts for ﹤0.01% of the portfolio, ranked #5144.

IFP Advisors first reported a position in ACTU in Q1 2026 and has held it in 3 quarters since. The position peaked at $112 in Q2 2026. 5 funds tracked by Wall St. Rank hold ACTU as of Q3 2026.

IFP Advisors held 26 shares of Actuate Therapeutics worth $20 as of Q3 2026.
IFP Advisors sold 47 Actuate Therapeutics shares in Q3 2026, an estimated $56.
Actuate Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #5144 holding.
IFP Advisors first reported a position in Actuate Therapeutics in Q1 2026 and has held it in 3 quarters since.
IFP Advisors's Actuate Therapeutics position peaked at $112 in Q2 2026.
5 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.